We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Jill Roberts Center for Inflammatory Bowel Disease

You are here

O-006 Expansion of Immunologically-Relevant E. Coli in the Intestinal Microbiota of Patients with IBD-Associated Spondyloarthritis Promotes Mucosal RORgt-Dependent Immunity.

TitleO-006 Expansion of Immunologically-Relevant E. Coli in the Intestinal Microbiota of Patients with IBD-Associated Spondyloarthritis Promotes Mucosal RORgt-Dependent Immunity.
Publication TypeJournal Article
Year of Publication2016
AuthorsKivolowitz C, Abdulhamid A, Victorio D, Castellanos J, Simpson K, Scherl E, Longman R
JournalInflamm Bowel Dis
Volume22 Suppl 1
PaginationS3
Date Published2016 Mar
ISSN1536-4844
Abstract

BACKGROUND: Spondyloarthritis (SpA) is the most common extra-intestinal manifestation in patients with inflammatory bowel disease (IBD), but the underlying pathogenesis that links IBD and SpA is unknown. Since IBD involves a dysregulated intestinal immune response to luminal microbial antigens and the abundance of particular microbial clades has been correlated to other arthropathies, we hypothesized that IBD-associated SpA (IBD-SpA) has a characteristic immunogenic microbial signature.

METHODS: To test this hypothesis, we evaluated the fecal microbiome of 59 IBD patients (40 Crohn's disease [CD], 19 ulcerative colitis [UC]) using 16S rRNA sequence analysis. The Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) and 44-point joint count was used to clinically characterize inflammatory joint disease activity. To profile the immunologically relevant fecal microbiota, we sorted and sequenced IgA- and IgG-coated microbes from CD and CD-SpA patients. To test the functional significance of patient-derived E. coli, we cultured isolates from IBD-SpA patients by limiting dilution anaerobic culture and assessed their effect on intestinal immune cell activity in gnotobiotic mice.

RESULTS: Of the patients evaluated, 34 patients had SpA based on the Assessment of Spondyloarthritis international Society (ASAS) guidelines (25 CD-SpA, 9 UC-SpA). BASDAI and 44-point joint count significantly differentiated IBD-SpA versus IBD controls (4.4 versus 2.4, P = 0.003; 3.1 versus 0.9, P = 0.03, respectively). Compositional analysis of the fecal microbiome revealed a significant expansion of Enterobacteriaceae in CD-SpA compared to CD alone. Significant enrichment in the OTU E. coli/Shigella was seen in IgA- and IgG-coated fractions of patients with CD-SpA. Colonization of germ-free C57BL/6 mice with IBD-SpA patient-derived E. coli robustly induced lamina propria T helper cells expressing RORgt+ (Th17) cells and Foxp3+/RORgt in vivo.

CONCLUSIONS: Our findings reveal that the intestinal microbiota of patients with IBD-SpA is selectively enriched in immunologically relevant E. coli and promote RORgt-dependent intestinal immunity. Follow up mechanistic studies will help to define potential diagnostic and therapeutic targets in the relationship between intestinal microbiota and IBD-associated SpA.

DOI10.1097/01.MIB.0000480044.73384.2d
Alternate JournalInflamm. Bowel Dis.
PubMed ID26849724